Alexis Benjamin Cortot

Alexis Benjamin Cortot

Auto-generated profile, based on publicly available information

Alexis Benjamin Cortot

CNRS, Inserm, Institut Pasteur de Lille, UMR9020‐UMR1277‐Canther‐Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille CHU Lille Lille France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Annals of Oncology
Verified
Journal Article
Open access
JMJulien Mazieres
Julien Mazieres
ADA. Drilon
A. Drilon
ALA. Lusque
A. Lusque
LML. Mhanna
L. Mhanna
ACA.B. Cortot
A.B. Cortot
OGO. Gautschi
O. Gautschi
Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation. We studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2). : ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
JSJean-Charles Soria
Jean-Charles Soria
DTDaniel S W Tan
Daniel S W Tan
RCRita Chiari
Rita Chiari
YWYI-LONG WU
YI-LONG WU
LPLuis Paz-Ares
Luis Paz-Ares
GCGilberto de Castro
Gilberto de Castro

24 December 2009 in Nature
Verified
Journal Article
Open access
PDF file
WZWenjun Zhou
Wenjun Zhou
DEDalia Ercan
Dalia Ercan
LCLiang Chen
Liang Chen
CYCai-Hong Yun
Cai-Hong Yun
DLDanan Li
Danan Li
PJPasi Antero Jänne
Pasi Antero Jänne
Non-small-cell lung tumours with activating mutations in the epidermal growth factor receptor (EGFR) often show a clinical response to receptor inhibitors, but tend to develop resistance due to the additional EGFR T790M mutations. Pasi Jänne and colleagues now have developed a new class of EGFR inhibitor that selectively inhibits the mutant receptor, rather that the wild type, and also inhibits the T790M mutant. These compounds reduce tumour growth in a mouse model and may prove more clinically effective and better tolerated than current EGFR kinase inhibitors in clinical use. Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) often show a clinical response to EGFR kinase inhibitors but tend to develop drug-resistance mutations, including the gatekeeper T790M mutation. Here, a new class of EGFR inhibitors is developed; these agents are 30- to 100-fold more potent against EGFR with the T790M mutation, and up to 100-fold less potent against wild-type EGFR, than current EGFR inhibitors. The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation1,2,3. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR4,5. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.

1 June 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJulien Mazieres
Julien Mazieres
SPSolange Peters
Solange Peters
BLBenoit Lepage
Benoit Lepage
ACAlexis B. Cortot
Alexis B. Cortot
FBFabrice Barlesi
Fabrice Barlesi
OGOliver Gautschi
Oliver Gautschi
Purpose: HER2 mutations are identified in approximately 2%of non–small-cell lung cancers (NSCLC). There are few data available that describe the clinical course of patients with HER2-mutated NSCLC. Patients and Methods: We retrospectively identified 65 NSCLC, diagnosed with a HER2 in-frame insertion in exon 20. We collected clinicopathologic characteristics, patients' outcomes, and treatments. Results: HER2 mutation was identified in 65 (1.7%) of 3,800 patients tested and was almost an exclusive driver, except for one single case with a concomitant KRAS mutation. Our population presented with a median age of 60 years (range, 31 to 86 years), a high proportion of women (45 women v 20 men; 69%), and a high proportion of never-smokers (n= 34; 52.3%). All tumors were adenocarcinomas and 50% were stage IV at diagnosis. For these latter cases, 22 anti–human epidermal growth factor receptor 2 (HER2) treatments were administered after conventional chemotherapy in 16 patients. Subsequently, four patients experienced progressive disease, seven experienced disease stabilizations, and 11 experienced partial responses (overall response rate, 50%; disease control rate [DCR], 82%). Specifically, we observed a DCR of 93% for trastuzumab-based therapies (n = 15) and a DCR of 100% for afatinib (n = 3) but no response to other HER2-targeted drugs (n = 3). Progression-free survival for patients with HER2 therapies was 5.1 months. Median survival was of 89.6 and 22.9 months for early-stage and stage IV patients, respectively. Conclusion: This study, the largest to date dedicated to HER2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.

1 December 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
EGEdward B Garon
Edward B Garon
TSTakashi Seto
Takashi Seto
MNMakoto Nishio
Makoto Nishio
SASantiago Ponce Aix
Santiago Ponce Aix
SDShaker Dakhil
Shaker Dakhil

23 November 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JMJulien Mazieres
Julien Mazieres
FBF. Barlesi
F. Barlesi
TFT. Filleron
T. Filleron
BBB. Besse
B. Besse
IMI. Monnet
I. Monnet
OGO. Gautschi
O. Gautschi
HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens. This retrospective cohort study in European centers assessed patients with advanced non-small-cell lung cancer (NSCLC), a known HER2 exon-20 insertion, treated with chemotherapy and/or HER2-targeted drugs. We identified 101 eligible patients from 38 centers: median age 61 years (range: 30–87), 62.4% women, 60.4% never-smokers. All tumors were adenocarcinomas. Concomitant EGFR mutations, ALK translocations, and ROS translocations were observed in 5, 1, and 1 patients, respectively. The median number of treatment lines was 3 (range: 1–11). The median overall survival was 24 months. Overall response rate (ORR) and the median progression-free survival (PFS) with conventional chemotherapy (excluding targeted therapies) were 43.5% and 6 months in first-line (n = 93), and 10% and 4.3 months in second-line (n = 52) therapies. Sixty-five patients received HER2-targeted therapies: trastuzumab = 57, neratinib = 14, afatinib = 9, lapatinib = 5, T-DM1 = 1. ORR was 50.9% and PFS was 4.8 months with trastuzumab or T-DM1. This series shows the chemosensitivity of HER2-driven NSCLC, and the potential interest of HER2-targeted agents. Our results should help to define the best therapeutic strategy for these patients and to orient future clinical trials.